Literature DB >> 35172053

Outpatient Remdesivir to Prevent Progression to Severe Covid-19. Reply.

Robert L Gottlieb1, Kavita Juneja2, Joshua A Hill3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35172053     DOI： 10.1056/NEJMc2200591

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial.

Authors:  Olli P O Nevalainen; Saana Horstia; Sanna Laakkonen; Jarno Rutanen; Jussi M J Mustonen; Ilkka E J Kalliala; Hanna Ansakorpi; Hanna-Riikka Kreivi; Pauliina Kuutti; Juuso Paajanen; Seppo Parkkila; Erja-Leena Paukkeri; Markus Perola; Negar Pourjamal; Andreas Renner; Tuomas Rosberg; Taija Rutanen; Joni Savolainen; Jari K Haukka; Gordon H Guyatt; Kari A O Tikkinen
Journal:  Nat Commun       Date:  2022-10-18       Impact factor: 17.694

2.  Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic.

Authors:  Giulia Garzi; Francesco Cinetto; Davide Firinu; Giulia Di Napoli; Gianluca Lagnese; Alessandra Punziano; Patrick Bez; Bianca Laura Cinicola; Giulia Costanzo; Riccardo Scarpa; Federica Pulvirenti; Marcello Rattazzi; Giuseppe Spadaro; Isabella Quinti; Cinzia Milito
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.